De novo genome assembly market seen reaching $3.96 billion by 2030

By AI, Created 4:30 PM UTC, May 18, 2026, /AGP/ – The de novo genome assembly market is projected to grow from $1.99 billion in 2025 to $3.96 billion by 2030, fueled by next-generation sequencing, personalized medicine and AI-driven bioinformatics. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - De novo genome assembly is becoming more important for personalized medicine, clinical diagnostics and genomics research. - The market’s projected growth signals rising demand for tools that can reconstruct genomes without a reference sequence. - The shift could speed discovery in rare disease, cancer, plant and microbial genomics, and evolutionary and environmental research.

What happened: - The Business Research Company released a 2026 market report on the global de novo genome assembly market. - The report said the market rose from $1.99 billion in 2025 to an expected $2.28 billion in 2026, a 14.6% compound annual growth rate. - The report forecast the market will reach $3.96 billion by 2030, growing at a 14.8% CAGR. - The report also framed de novo genome assembly as reconstructing a complete genome from short DNA fragments without a reference genome. - The source included a free sample request and the full report.

The details: - Growth drivers in the near term include wider use of next-generation sequencing, more academic research, greater use of genome assembly software and rising clinical diagnostics demand. - Plant and microbial genomics projects are also adding momentum. - Longer-term growth is expected from AI in assembly workflows, cloud-based bioinformatics platforms, rapid custom genome sequencing, precision medicine applications, and more investment in evolutionary and environmental genomics. - Expected trends include automated genome assembly pipelines, cloud data analytics, high-throughput sequencing integration, tailored bioinformatics services, and better genome visualization and annotation tools. - The report said personalized medicine is a key growth factor because genomic data helps tailor treatments to genetic profiles, biomarkers and disease characteristics. - De novo genome assembly can identify novel genetic variants and structural changes that support precision therapies, drug selection and early disease detection. - In February 2024, the Personalized Medicine Coalition said the U.S. Food and Drug Administration approved 16 new personalized therapies for rare disease patients in 2023, up from six in 2022. - Those approvals included seven cancer treatments and three for other conditions.

Between the lines: - The market forecast suggests genomics is moving from research use toward more operational clinical and commercial workflows. - AI and cloud adoption point to a broader shift toward faster, more scalable bioinformatics. - Personalized medicine is acting as a demand engine because each new therapy category can increase the need for genome reconstruction and interpretation. - The report’s regional callout suggests mature research funding still matters, but faster growth may now be shifting toward newer genomics markets in Asia-Pacific.

What’s next: - North America is expected to keep the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region through the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - More adoption of automated pipelines and cloud bioinformatics could shape competitive positioning through 2030.

The bottom line: - De novo genome assembly is moving deeper into the mainstream of precision medicine and genomic research, and the market outlook points to sustained double-digit growth through 2030.